Etavopivat is a medication being studied for treating blood disorders, specifically sickle cell disease and thalassemia. It works by modifying how red blood cells function to help improve their shape and survival in people with these conditions. This medication is being tested as a long-term treatment option for adults, adolescents, and children who have previously participated in other studies using this same drug.

Sickle Cell Disease – A genetic blood disorder where red blood cells become crescent-shaped instead of round. These abnormal cells can get stuck in blood vessels, causing pain and blocking blood flow. The condition is present from birth and affects how oxygen is delivered throughout the body. The altered blood cells break down faster than normal ones, leading to anemia.

Thalassemia – A hereditary blood condition where the body makes an abnormal form or inadequate amount of hemoglobin. The disorder leads to the destruction of red blood cells, resulting in anemia. There are different types of thalassemia, varying in severity depending on the specific genetic changes involved. The condition affects the body’s ability to produce normal adult hemoglobin, which is essential for carrying oxygen throughout the body.